# (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

> **NCT04996875** · PHASE2 · RECRUITING · sponsor: **Cogent Biosciences, Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Systemic Mastocytosis (AdvSM)
- SM With an Associated Hematologic Neoplasm (SM-AHN)
- Mast Cell Leukemia (MCL)
- Aggressive Systemic Mastocytosis (ASM)

## Interventions

- **DRUG:** bezuclastinib

## Key facts

- **NCT ID:** NCT04996875
- **Lead sponsor:** Cogent Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-09
- **Primary completion:** 2025-09-19
- **Final completion:** 2027-07
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996875, "(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04996875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*